Lower-limb neuromuscular electrical stimulation (NMES) for adults with kidney failure undergoing dialysis.

Cochrane Database Syst RevSep 18, 2026 (epub)
Clinical ResearchNephrology

Louise Beresford, Louise C Burgess, Susan Dewhurst et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effects of lower-limb neuromuscular electrical stimulation (NMES) on critical outcomes in adults with kidney failure undergoing dialysis. The analysis included 12 randomized controlled trials with a total of 299 participants. NMES was associated with improvements in muscle function and physical performance compared to no NMES, highlighting its potential as an adjunct therapy in this population.

Key findings

  • NMES significantly improved muscle function compared to no NMES.
  • Participants receiving NMES showed enhanced physical performance metrics.
  • The review included data from 12 randomized controlled trials.
  • A total of 299 participants contributed to the analysis after accounting for withdrawals.

Why it matters

The findings suggest that NMES may serve as a beneficial intervention for improving muscle function and physical performance in dialysis patients, addressing a critical aspect of their care and potentially enhancing their quality of life.

Source

PubMed · PMID 42757634

Published in Cochrane Database Syst Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.